COVID-19 infection in a membranous nephropathy patient treated with rituximab.
CEN Case Rep
; 10(1): 83-87, 2021 02.
Article
in English
| MEDLINE | ID: covidwho-746988
ABSTRACT
While COVID-19 pandemic continues to affect our country and most countries in the world, we have to make some changes both in our social life and our approach to healthcare. We have to struggle with the pandemic on one hand and also try to follow up and treat our patients with chronic diseases in the most appropriate way. In this period, one of our group of patients who are challenging us for follow-up and treatment are those who should start or continue to use immunosuppressive therapy. In order to contribute to the accumulation of knowledge in this area, we wanted to report a patient who was followed up with the diagnosis of COVID-19 and had been administered rituximab very recently due to a nephrotic syndrome caused by membranous nephropathy.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Glomerulonephritis, Membranous
/
Immunocompromised Host
/
COVID-19
Type of study:
Case report
/
Cohort study
/
Prognostic study
Topics:
Long Covid
Limits:
Humans
/
Male
/
Middle aged
Language:
English
Journal:
CEN Case Rep
Year:
2021
Document Type:
Article
Affiliation country:
S13730-020-00524-3
Similar
MEDLINE
...
LILACS
LIS